#Israel #Lumenis #Yokne'am Illit #Stellar M22 #XPL Technology

Lumenis Unveils Stellar M22™ at ASDS 2025

On November 18, 2025, Lumenis Be. Ltd., a leader in energy-based medical technologies, introduced its latest innovation, the Stellar M22™ skin treatment platform, at the Annual American Society for Dermatologic Surgery (ASDS) Meeting. Featuring the pioneering XPL™ (Expert Pulsed Light) Technology, this next-generation system is designed to address over 30 different skin conditions with remarkable efficacy and safety across diverse demographics.

A New Standard in Aesthetic Treatments

The Stellar M22™ integrates advanced multi-application technologies, including XPL™, ResurFX®, NdYAG, and Q-Switched NdYAG, into one compact system that not only optimizes treatment workflows but also improves patient outcomes significantly. Backed by clinical data, the platform has shown at least a 70% improvement in results after just one session, making it a game-changer for aesthetic professionals. The introduction of the XPL Glide Mode further enhances treatment efficiency, allowing practitioners to perform comfortable and swift treatments that cover larger areas without compromising quality.

Technology Advancements and Features

The Stellar M22™ stands out with innovative features such as:

• - Expert Pulsed Light Technology: This technology encompasses eight expert filters and advanced pulse parameters, providing precise control over treatment settings tailored to individual patient needs.
• - Diverse Treatment Modalities: The platform effectively addresses uneven skin tone, large vascular lesions, dark tattoo removal, and more, catering to various skin types and concerns.
• - ResurFX® BrushFX™ Mode: This new feature delivers natural-looking skin textures with an airbrush-like finish, which is particularly desirable in aesthetic treatments.
• - Hybrid Treatment Modalities: Combining multiple technologies like SmoothGlo™ and PhotoFABULOUS™, the Stellar M22™ offers comprehensive solutions that rejuvenate skin texture, tone, and volume effectively.

Clinical Validation

During the ASDS meeting, Lumenis presented impressive clinical results from studies demonstrating a clearance rate of 76-100% for cutaneous lesions within a single session of XPL treatment. Dr. Gilly Munavalli, a prominent figure in dermatology, emphasized the platform's ability to surpass previous models in both efficiency and patient comfort. He remarked, "The Stellar M22™, refined over 30 years, consistently delivers superb clinical outcomes, making it an essential tool in any aesthetic practice."

Empowering Aesthetic Practices

With over 850 built-in expert protocols, the Stellar M22™ streamlines treatment delegation, ensuring consistent and repeatable results across practice teams. This innovative platform enables providers to expand their service offerings while meeting the rising patient demand for effective skin treatments. As the energy-based skincare market continues to thrive, the Stellar M22™ remains at the forefront, helping practitioners upscale their services with maximum versatility and minimum downtime.

Conclusion

In summary, the Stellar M22™ represents a significant leap forward in aesthetic technology. By merging advanced engineering with clinical validation, Lumenis delivers a product that not only elevates the standard of care in skin treatments but also empowers both practitioners and patients to achieve their aesthetic goals. For more details about this groundbreaking platform, visit Lumenis.com/StellarM22.

About Lumenis

Lumenis is a renowned leader in the medical aesthetics and eye care industries, known for developing innovative energy-based technologies for over 50 years. The company has consistently set benchmarks in treatment effectiveness and safety, striving to revolutionize care for previously untreatable conditions. As a part of the EQT Group's portfolio, Lumenis continues to shape the future of aesthetic treatments worldwide.